Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission, at Discharge a… (NCT04930302) | Clinical Trial Compass
CompletedNot Applicable
Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission, at Discharge and at Post-discharge Check-up: Quasi-experimental Clinical Uncontrolled Trial (PHAROS)
Slovakia105 participantsStarted 2021-09-01
Plain-language summary
This project aims to assess the impact of pharmaceutical care in collaboration with physicians on prevalence of DRPs at hospital admission and discharge in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.
The key focus area of this project will be the identification of DRPs, their occurrence and type. As a part of further research, the investigators want to analyze the a) acceptance rate of pharmaceutical intervention by physicians. Proportion of accepted interventions by physicians was calculated and b) patients' understanding of his/her pharmacotherapy assessed on a three-point scale at hospital admission.
Hypothesis:
Null hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge does not reduce prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.
Alternative hypothesis: Pharmaceutical care provided at hospital admission and at hospital discharge reduces prevalence rates of DRPs in patients with carotid artery disease or lower extermity artery disease hospitalized at the Department of Vascular Surgery.
Primary outcomes:
Change in the prevalence rate of DRPs at hospital admission vs. hospital discharge.
Secondary outcomes:
1. acceptance rate of pharmaceutical intervention by physician
2. patients' understanding of his/her pharmacotherapy
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥18 years at the date of admission for hospitalization
. patients taking at least 3 medications
. patients with carotid artery disease or lower extremity artery disease
Exclusion criteria
. Acute patients.Due to the urgent health condition, medication reconciliation is not the priority in these patients, furthermore, rendering the BPMH collection impossible.
. Patients transferred from other hospitals/wards
. Not willing to sign the informed consent form for the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in prevalence rate of drug related problems
Timeframe: through study completion, an average of 1 year
Trial details
NCT IDNCT04930302
SponsorNational Institute of Cardiovascular Diseases, Slovakia
. Presence of any mental disorder affecting memory and recall ability (such as Alzheimer's disease)
. Any other reason at the discretion of the investigator why he/she deems the participant not eligible for study participation (all such reasons will be recorded)
. Participation in another clinical study
. Furthermore, patients transferred to other hospitals/wards will be excluded from the study.